Immix Biopharma (IMMX) Earnings Analysis
Immix Biopharma (IMMX) next reports earnings on 2026-08-14, consensus EPS -0.17 USD. Last quarter (2026-05-07) it beat with EPS -0.18 USD vs -0.18055 USD est (+0.3%). It has beaten estimates in 4/7 recent quarters (57%). Trailing P/E -10.23.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does IMMX next report earnings?
| Next earnings date | 2026-08-14 |
|---|---|
| Consensus EPS estimate | -0.17 USD |
| Revenue estimate | n/a |
IMMX earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-07 | -0.18 USD | -0.18055 USD | +0.3% | Beat |
| 2026-03-25 | -0.27 USD | -0.21 USD | -28.6% | Miss |
| 2025-11-07 | -0.24 USD | -0.19 USD | -26.3% | Miss |
| 2025-08-08 | -0.22 USD | -0.21 USD | -4.8% | Miss |
| 2025-05-08 | -0.15 USD | -0.23 USD | +34.8% | Beat |
| 2025-03-24 | -0.16 USD | -0.25 USD | +36% | Beat |
| 2024-08-12 | -0.15 USD | -0.21 USD | +28.6% | Beat |
Beat rate: 4/7 (57%) over reported quarters with consensus data.
IMMX valuation and analyst view
| Trailing P/E | -10.23 |
|---|---|
| Trailing EPS | -0.91372 USD |
| Price / book | 4.27 |
| Dividend yield | 0.00% |
| Market cap | 0.51B |
| Analyst consensus | Buy (4 buy / 0 hold / 0 sell) |
| Avg price target | 20 USD |
Related research pages
Frequently asked questions
When is Immix Biopharma (IMMX)'s next earnings date?
Immix Biopharma is next scheduled to report on 2026-08-14, with a consensus EPS estimate of -0.17 USD.
Did IMMX beat earnings last quarter?
In its 2026-05-07 report, IMMX posted EPS of -0.18 USD versus a -0.18055 USD estimate — a beat of 0.3%.
What is IMMX's earnings track record?
Over the last 7 reported quarters with consensus data, IMMX beat estimates 4 times (57%).
What is IMMX's current P/E ratio and EPS?
IMMX trades at a trailing P/E of -10.23 on trailing EPS of -0.9137195321666998 USD.
What do analysts rate IMMX?
Analyst consensus is "Buy" across 4 ratings (0 strong buy, 4 buy, 0 hold, 0 sell, 0 strong sell). Average 12-month price target: 20 USD.